PET-based molecular imaging in neuroscience.
Positron emission tomography (PET) allows non-invasive assessment of physiological, metabolic and molecular processes in humans and animals in vivo. Advances in detector technology have led to a considerable improvement in the spatial resolution of PET (1-2 mm), enabling for the first time investigations in small experimental animals such as mice. With the developments in radiochemistry and tracer technology, a variety of endogenously expressed and exogenously introduced genes can be analysed by PET. This opens up the exciting and rapidly evolving field of molecular imaging, aiming at the non-invasive localisation of a biological process of interest in normal and diseased cells in animal models and humans in vivo. The main and most intriguing advantage of molecular imaging is the kinetic analysis of a given molecular event in the same experimental subject over time. This will allow non-invasive characterisation and "phenotyping" of animal models of human disease at various disease stages, under certain pathophysiological stimuli and after therapeutic intervention. The potential broad applications of imaging molecular events in vivo lie in the study of cell biology, biochemistry, gene/protein function and regulation, signal transduction, transcriptional regulation and characterisation of transgenic animals. Most importantly, molecular imaging will have great implications for the identification of potential molecular therapeutic targets, in the development of new treatment strategies, and in their successful implementation into clinical application. Here, the potential impact of molecular imaging by PET in applications in neuroscience research with a special focus on neurodegeneration and neuro-oncology is reviewed.
Jacobs
A H
AH
Laboratory for Gene Therapy and Molecular Imaging, Max-Planck-Institute for Neurological Research, Gleuelerstrasse 50, 50931, Cologne, Germany. Andreas.Jacobs@pet.mpin-koeln.mpg.de
Li
H
H
Winkeler
A
A
Hilker
R
R
Knoess
C
C
Rüger
A
A
Galldiks
N
N
Schaller
B
B
Sobesky
J
J
Kracht
L
L
Monfared
P
P
Klein
M
M
Vollmar
S
S
Bauer
B
B
Wagner
R
R
Graf
R
R
Wienhard
K
K
Herholz
K
K
Heiss
W D
WD
D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D005786:Gene Expression Regulation / Q000502:physiology*; D005910:Glioma / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D009488:Neurosciences / Q000295:instrumentation / Q000379:methods; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D021381:Protein Transport / Q000502:physiology; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed / Q000295:instrumentation / Q000379:methods*
D011506:Proteins; D019275:Radiopharmaceuticals